Molecular Tumor Board

Many of the current HIPO2 projects run in analog manner to established registry trials such as the NCT MASTER program or INFORM, which were established to allow for prospective whole-exome/genome and transcriptome sequencing within a clinical context. In this multidisciplinary initiative molecular data are generated and subsequently evaluated from a clinical perspective in molecular tumor boards with the goal to formulate treatment recommendations for individualized patient care. The molecular tumor board members include translational oncologists, bioinformaticians, molecular biologists, pathologists, and geneticists.

Contact:

NCT-MASTER: This email address is being protected from spambots. You need JavaScript enabled to view it.

INFORM: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 

 

DKFZ Logo 3zu Research en Black Blue sRGB

4c nctlogo 2009